Suppressive Immune Response of Poly(sarcosine) Conjugated Proteins: PSARylation.
Open Access
- 15 July 2026
- journal article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
Abstract
Polymer conjugation is a widely used strategy to improve the pharmacokinetics of protein therapeutics by extending their half-life and protecting them from degradation. Poly(ethylene glycol) (PEG) is the most commonly used polymer for this purpose. However, its use can trigger unwanted immune responses, leading to the production of anti-PEG antibodies that compromise efficacy. This issue has driven the search for alternative polymers, with poly(sarcosine) (PSAR), derived from an endogenous amino acid, emerging as a promising candidate. Despite this potential, the immunogenicity of PSAR-protein conjugates (PSARylation) has not been systematically compared with that of PEGylated counterparts. In this report, we show that conjugating a model protein antigen to high-molecular-weight PSAR more effectively suppresses immune responses against both the protein and the polymer than PEG. Although polymer conjugation has traditionally been viewed as a means of steric "masking" of a protein, our results demonstrate that the chemical nature of the polymer is a critical, independent factor, as PSAR conjugates elicited lower antibody production than PEG conjugates of identical hydrodynamic size. This study highlights polymer selection as an important design parameter for minimizing immunogenicity in next-generation protein therapeutics. Polymers derived from biological building blocks, such as PSAR, offer a promising route to developing safer, more effective biopharmaceuticals with better tolerance and reduced risk of adverse immune reactions.Keywords
Funding Information
- Japan Society for the Promotion of Science (21K19931)
- Japan Society for the Promotion of Science (23H03750)
- Japan Society for the Promotion of Science (23K13803)
- Japan Society for the Promotion of Science (23K25177)
- Japan Society for the Promotion of Science (23KK0204)
- Mukai Science and Technology Foundation (MZR2024004)
- Kansai University Research Branding Project
- Tobe Maki Foundation (25-JA-013)
- Kansai University Fund for Supporting Young Scholars
This publication has 44 references indexed in Scilit:
- PEGylated therapeutics in the clinicBioengineering & Translational Medicine, 2023
- Well‐Defined Anisotropic Self‐Assembly from Peptoids and Their Biomedical ApplicationsChemMedChem, 2023
- Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic ProteinsBioDrugs, 2021
- Precision Conjugation: An Emerging Tool for Generating Protein–Polymer ConjugatesAngewandte Chemie International Edition, 2020
- Poly(Sarcosine) Surface Modification Imparts Stealth‐Like Properties to LiposomesSmall, 2019
- Modulation of immunogenicity of poly(sarcosine) displayed on various nanoparticle surfaces due to different physical propertiesJournal of Peptide Science, 2017
- Control of in vivo disposition and immunogenicity of polymeric micelles by adjusting poly(sarcosine) chain lengths on surfaceJournal of Nanoparticle Research, 2017
- Suppressive immune response of poly‐(sarcosine) chains in peptide‐nanosheets in contrast to polymeric micellesJournal of Peptide Science, 2014
- PEGylation of therapeutic proteinsBiotechnology Journal, 2010
- Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patientsCancer, 2007